Article Details
Retrieved on: 2024-09-11 16:58:53
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses BridgeBio Pharma's FDA Regenerative Medicine Advanced Therapy (RMAT) designation for BBP-812, a gene therapy for Canavan disease, highlighting its significance for regenerative medicine and policies around rare diseases.
Article found on: www.worldpharmaceuticals.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here